Back to Journals » Diabetes, Metabolic Syndrome and Obesity » Volume 6
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
Authors Gallwitz B
Received 27 September 2012
Accepted for publication 29 November 2012
Published 4 January 2013 Volume 2013:6 Pages 1—9
DOI https://doi.org/10.2147/DMSO.S23166
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Baptist Gallwitz
Department of Medicine IV, Eberhard-Karls-University Tübingen, Tübingen, Germany
Abstract: The first dipeptidyl-peptidase-IV (DPP-4) inhibitor for the treatment of type 2 diabetes became available in 2006. Since then, the number of DPP-4 inhibitors has increased and DPP-4 inhibitors have developed into an important drug class. DPP-4 inhibitors act by increasing endogenous GLP-1 and GIP concentrations. Via this mechanism, insulin secretion is glucose-dependently stimulated and glucagon secretion inhibited. This results in a low risk for hypoglycemia. Furthermore, DPP-4 inhibitors are weight-neutral. Linagliptin is a novel DPP-4 inhibitor that, in contrast to the other members of this drug class, is eliminated by a biliary/hepatic route rather than by renal elimination. This property allows the use of linagliptin in type 2 diabetic patients with normal kidney function as well as in patients with renal insufficiency without dose adjustments. In comparative clinical studies, linagliptin was noninferior to other established antidiabetic agents, especially to metformin and sulfonylurea. It showed a superior safety profile over glimepiride regarding hypoglycemia, weight gain, a composite cardiovascular endpoint, and stroke. This review gives an overview on the efficacy and safety of linagliptin in comparison to the classical oral antidiabetic drugs as well as to the other DPP-4 inhibitors.
Keywords: type 2 diabetes, oral antidiabetic drugs, incretin-based therapies, DPP-4 inhibitors, linagliptin
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The
full terms of this license are available at https://www.dovepress.com/terms.php
and incorporate the Creative Commons Attribution
- Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted
without any further permission from Dove Medical Press Limited, provided the work is properly
attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.